Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Arthritis Rheum ; 60(10): 3128-38, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19790052

ABSTRACT

OBJECTIVE: Erdheim-Chester disease (ECD) is a rare form of non-Langerhans' cell histiocytosis. The aim of this study was to assess the value of whole-body scanning with (18)F-fluorodeoxyglucose-positron emission tomography (FDG-PET) in a large cohort of ECD patients from a single center. METHODS: We retrospectively reviewed all PET scans performed on 31 patients with ECD who were referred to our department between 2005 and 2008. PET images were reviewed by 2 independent nuclear medicine specialist physicians and were compared with other imaging modalities performed within 15 days of each PET scan. RESULTS: Thirty-one patients (10 women and 21 men; median age 59.5 years) underwent a total of 65 PET scans. Twenty-three patients (74%) were untreated at the time of the initial PET scan, whereas 30 of the 34 followup PET scans (88%) were performed in patients who were undergoing immunomodulatory therapy. Comparison of the initial and followup PET scans with other imaging modalities revealed that the sensitivity of PET scanning varied greatly among the different organs studied (range 4.3-100%), while the specificity remained high (range 69.2-100%). Followup PET scans were particularly helpful in assessing central nervous system (CNS) involvement, since the PET scan was able to detect an early therapeutic response of CNS lesions, even before magnetic resonance imaging showed a decrease in their size. PET scanning was also very helpful in evaluating the cardiovascular system, which is a major prognostic factor in ECD, by assessing the heart and the entire vascular tree during a single session. CONCLUSION: The results of our large, single-center, retrospective study suggest that the findings of a FDG-PET scan may be interesting in the initial assessment of patients with ECD, but its greater contribution is in followup of these patients.


Subject(s)
Erdheim-Chester Disease/diagnostic imaging , Positron-Emission Tomography/methods , Severity of Illness Index , Whole Body Imaging/methods , Adult , Aged , Cohort Studies , Female , Fluorodeoxyglucose F18 , Follow-Up Studies , Humans , Male , Middle Aged , Observer Variation , Retrospective Studies , Sensitivity and Specificity
2.
Artif Intell Med ; 47(2): 147-58, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19481429

ABSTRACT

OBJECTIVE: Alzheimer's disease (AD) and frontotemporal dementia (FTD) are among the most frequent neurodegenerative cognitive disorders, but their differential diagnosis is difficult. The aim of this study was to evaluate an automatic method returning the probability that a patient suffers from AD or FTD from the analysis of brain perfusion single photon emission computed tomography images. METHODS AND MATERIALS: A set of 116 descriptors corresponding to the average activity in regions of interest was calculated from the images of 82 AD and 91 FTD patients. A set of linear (logistic regression and linear discriminant analysis) and non-linear (support vector machines, k-nearest neighbours, multilayer perceptron and kernel logistic PLS) classification methods was subsequently used to ascertain diagnoses. Validation was carried out by means of the leave-one-out protocol. Diagnoses by the classifier and by four physicians (visual assessment) were compared. Since images were acquired in different hospitals, the impact of the medical centre on the diagnosis of both the classifier and the physicians was investigated. RESULTS: Best results were obtained with support vector machine and partial least squares regression coupled with k-nearest neighbours methods (PLS+K-NN), with an overall accuracy of 88%. PLS+K-NN was however considered as the best method since performances obtained with leave-one-out cross-validation were closer to whole-database learning. The performances of the classifier were higher than those of experts (accuracy ranged from 65 to 72%). Physicians found it more difficult to diagnose the images from centres other than their own, and it affected their performances. CONCLUSIONS: The performances obtained by the classifier for the differential diagnosis of AD and FTD were found convincing. It could help physicians in daily practice, particularly when visual assessment is inconclusive, or when dealing with multicentre data.


Subject(s)
Alzheimer Disease/diagnostic imaging , Automation , Dementia/diagnostic imaging , Aged , Aged, 80 and over , Female , Humans , Male , Tomography, Emission-Computed, Single-Photon
3.
Nucl Med Commun ; 30(7): 513-8, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19451839

ABSTRACT

OBJECTIVES: Nicotine therapy might improve the course of Parkinson's disease. This observational study evaluated the performance of dopamine transporter imaging in follow-up patients under nicotine therapy. METHODS: Six Hoehn and Yahr stage III patients underwent 123I-FP-CIT imaging prior to, 3 months, and 1 year after the onset of nicotine therapy. Nicotine was administered transdermally with increasing daily doses during 3 months (up to 105 mg/day) and decreased progressively. On co-registered magnetic resonance imaging, striatal regions of interest were drawn and binding potentials of 123I-FP-CIT were calculated.Changes in Unified Parkinson's Disease Rating Scale-III over time were compared with binding potentials using regression analysis. RESULTS: All patients improved motor scores at 3 months (-65 +/- 22% 'off', -89 +/- 12% 'on') and most received fewer dopaminergic drugs (-30% dosage in average). Motor improvement persisted to a lesser extent at 1 year(-39 +/- 31% 'off', -13 +/- 43% 'on'), partly because one patient stopped the treatment. Interestingly, the decrease in binding potentials (-4.0 +/- 10.5%) was slower than that expected in Parkinsonian patients (usually -10% per year) and was inversely correlated with Unified Parkinson's Disease Rating Scale-III improvement, r= 0.83 'off' and 0.91 'on'. CONCLUSION: This observational study emphasizes a potential effect of nicotine therapy on striatal dopamine transporter density, which may be interpreted as direct pharmacological effect or deceleration of neuronal loss.


Subject(s)
Dopamine Plasma Membrane Transport Proteins/metabolism , Nicotine/administration & dosage , Nicotine/therapeutic use , Parkinson Disease/drug therapy , Parkinson Disease/metabolism , Administration, Cutaneous , Dopamine Plasma Membrane Transport Proteins/analysis , Dose-Response Relationship, Drug , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Neostriatum/drug effects , Neostriatum/physiopathology , Parkinson Disease/diagnostic imaging , Regression Analysis , Time Factors , Tomography, Emission-Computed, Single-Photon , Tropanes
4.
Arthritis Rheum ; 60(4): 1193-200, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19333926

ABSTRACT

OBJECTIVE: (18)F-fluorodeoxyglucose-positron emission tomography (FDG-PET) scanning has been proposed as a new way of assessing disease activity in Takayasu arteritis (TA), but previous studies have used the nonvalidated National Institutes of Health (NIH) global activity criteria, and thus might be biased. This study was undertaken to determine the value of PET scanning for assessment of disease activity in TA, by comparing PET scan data with clinical, biologic, and magnetic resonance imaging (MRI) data assessed separately. METHODS: Twenty-eight patients with TA (according to the American College of Rheumatology criteria) underwent a total of 40 PET scans. Images were reviewed by 2 pairs of independent nuclear medicine physicians and assessed for pattern and intensity of vascular uptake. TA activity data were obtained within 15 days of the PET scans. RESULTS: PET scanning revealed abnormal vascular uptake in 47% of the 40 examinations. The uptake intensity grade was 0 in 7 scans, grade 1 in 7 scans, grade 2 in 13 scans, and grade 3 in 13 scans. Morphologic analysis was conducted by grading the pattern of the vascular uptake as diffuse (73%), segmental (20%), or focal (13%). There was a trend toward an association between clinically active disease and the semiquantitative assessment of FDG uptake (P = 0.08). We found no statistical association between levels of acute-phase reactants and intensity of uptake. There was no significant association between the semiquantitative assessment of FDG uptake and the presence of vascular wall thickening (P = 0.23), gadolinium uptake (P = 0.73), or the presence of vascular wall edema (P = 0.56). CONCLUSION: Our findings indicate that there is no association between FDG vascular uptake intensity and clinical, biologic, or MRI assessment of disease activity. Previous studies using the nonvalidated NIH global activity criteria are likely biased.


Subject(s)
Fluorodeoxyglucose F18 , Positron-Emission Tomography/methods , Positron-Emission Tomography/standards , Radiopharmaceuticals , Takayasu Arteritis/diagnostic imaging , Adolescent , Adult , Female , Follow-Up Studies , Humans , Male , Middle Aged , Reproducibility of Results , Retrospective Studies , Severity of Illness Index , Young Adult
5.
J Nucl Med ; 48(9): 1459-67, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17704252

ABSTRACT

UNLABELLED: (123)I-FP-CIT ((123)I-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iodophenyl)nortropane) is a SPECT dopamine transporter (DAT) tracer that probes dopaminergic cell loss in Parkinson's disease (PD). Quantification of (123)I-FP-CIT images is performed at equilibrium using a ratio (BR) of specific (striatal) to nonspecific (occipital) uptake with values obtained from regions of interest drawn manually over these structures. Statistical parametric mapping (SPM) is a fully automated voxel-based statistical approach that has great potential in the context of DAT imaging. However, the accuracy of the spatial normalization provided by SPM has not been validated for (123)I-FP-CIT images. Our first aim was to create an (123)I-FP-CIT template that does not require the acquisition of patient-specific MRI and to validate the spatial normalization procedure. Next, we hypothesized that this customized template could be used by different SPECT centers without affecting the outcomes of imaging analyses. METHODS: The spatial normalization to the customized template created with SPM (template A1) was validated using (123)I-FP-CIT images obtained from 6 subjects with essential tremor (ET) with normal DAT status and 6 PD patients. Variability in BR values due to the normalization was evaluated using striatal volume of interest (VOI). To determine whether different SPECT centers could use a unique (123)I-FP-CIT template, we generated 3 other (123)I-FP-CIT templates using different subjects and image-processing schemes. The interchangeability of these templates was assessed using (a) putamen BR values analyzed with the intraclass correlation coefficient (ICC) and the Bland-Altman graphical analysis, and (b) SPM analysis comparing the results of group comparisons-that is, ET versus PD, obtained after normalization to each of the 4 templates. RESULTS: There was no significant difference between pre- and post-normalization striatal BR values in our study. The mean variability calculated with putamen VOI values after normalization to each template was <10%, with the lowest ICC of 98%. Intergroup analyses performed with VOI and SPM approaches provided similar results independently of the template used. CONCLUSION: SPM normalization was accurate even in subjects with low striatal (123)I-FP-CIT uptake, making it a promising approach for automatic analysis of (123)I-FP-CIT images using a single customized template at different centers.


Subject(s)
Brain/diagnostic imaging , Essential Tremor/diagnostic imaging , Parkinson Disease/diagnostic imaging , Radiopharmaceuticals , Tropanes , Aged , Brain/metabolism , Data Interpretation, Statistical , Dopamine Plasma Membrane Transport Proteins/metabolism , Female , Humans , Image Processing, Computer-Assisted , Magnetic Resonance Imaging , Male , Middle Aged , Pilot Projects , Radionuclide Imaging
6.
Eur J Nucl Med Mol Imaging ; 33(1): 87-92, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16180033

ABSTRACT

PURPOSE: The purpose of this study was to investigate the feasibility and utility of dual-isotope SPECT for differential diagnosis of idiopathic Parkinson's disease (IPD) and multiple system atrophy (MSA). METHODS: Simultaneous (99m)Tc-ECD/123I-FP-CIT studies were performed in nine normal controls, five IPD patients, and five MSA patients. Projections were corrected for scatter, cross-talk, and high-energy penetration, and iteratively reconstructed while correcting for patient-specific attenuation and variable collimator response. Perfusion and dopamine transporter (DAT) function were assessed using voxel-based statistical parametric mapping (SPM2) and volume of interest quantitation. DAT binding potential (BP) and asymmetry index (AI) were estimated in the putamen and caudate nucleus. RESULTS: Striatal BP was lower in IPD (55%) and MSA (23%) compared to normal controls (p<0.01) , and in IPD compared to MSA (p<0.05). AI was greater for IPD than for MSA and controls in both the caudate nucleus and the putamen (p<0.05). There was significantly decreased perfusion in the left and right nucleus lentiformis in MSA compared to IPD and controls (p<0.05). CONCLUSION: Dual-isotope studies are both feasible in and promising for the diagnosis of parkinsonian syndromes.


Subject(s)
Cysteine/analogs & derivatives , Image Enhancement/methods , Multiple System Atrophy/diagnostic imaging , Organotechnetium Compounds , Parkinson Disease/diagnostic imaging , Tropanes , Diagnosis, Differential , Feasibility Studies , Female , Humans , Male , Middle Aged , Radionuclide Imaging , Reproducibility of Results , Sensitivity and Specificity
7.
Spine (Phila Pa 1976) ; 29(5): E85-7, 2004 Mar 01.
Article in English | MEDLINE | ID: mdl-15129086

ABSTRACT

STUDY DESIGN: A case of atypical osseous tuberculosis (TB) mimicking multiple secondary metastases on radiologic and nuclear imaging is presented. OBJECTIVES: To emphasize the contribution of nuclear bone scanning for the assessment of osseous tuberculosis in typical and atypical presentations. SUMMARY AND BACKGROUND DATA: Skeletal locations of TB mostly involve the dorsolumbar spine and diagnosis is often delayed. The presence of multiple TB sites can mimic secondary metastases and biopsy remains the mainstay for final diagnosis. METHODS: Clinical symptoms, lab tests, and imaging data are presented. Possible diagnoses are discussed. A review of imaging characteristics in cases of typical and atypical presentations of osseous TB is proposed. RESULTS: A dorsal spine spondylitis was first diagnosed on a 56-year-old patient presenting neurologic deficit of the left arm. Fine needle aspiration identified bacterial infection but was negative for Mycobacterium tuberculosis. Whole-body bone scan allowed the identification of an asymptomatic sacroiliac lesion, which was accessible to biopsy and gave a final diagnosis. CONCLUSION: Nuclear bone scanning should be kept in mind when assessing spinal pain in patients at high risk of TB infection or reactivation.


Subject(s)
Lumbar Vertebrae/diagnostic imaging , Radiopharmaceuticals , Sacrum/diagnostic imaging , Spinal Neoplasms/secondary , Spondylitis/diagnostic imaging , Technetium Tc 99m Medronate/analogs & derivatives , Thoracic Vertebrae/diagnostic imaging , Tuberculosis, Osteoarticular/diagnostic imaging , Africa, Northern/ethnology , Arm , Back Pain/etiology , Biopsy, Fine-Needle , Diabetes Complications , Diagnosis, Differential , Epidural Abscess/etiology , Epidural Abscess/microbiology , False Negative Reactions , Humans , Lumbar Vertebrae/microbiology , Male , Middle Aged , Mycobacterium tuberculosis/isolation & purification , Osteolysis/etiology , Paralysis/etiology , Radionuclide Imaging , Recurrence , Sacroiliac Joint/diagnostic imaging , Spinal Neoplasms/complications , Spinal Neoplasms/diagnostic imaging , Spondylitis/microbiology , Spondylitis/pathology , Thoracic Vertebrae/microbiology , Tuberculoma/diagnostic imaging , Tuberculoma/pathology , Tuberculosis, Osteoarticular/microbiology , Tuberculosis, Osteoarticular/pathology
8.
J Nucl Med ; 44(9): 1459-66, 2003 Sep.
Article in English | MEDLINE | ID: mdl-12960192

ABSTRACT

UNLABELLED: Imaging techniques have demonstrated in various cardiomyopathies that an altered uptake of radiolabeled norepinephrine (NE) analogs may coexist with beta-adrenergic receptor downregulation, but the relationships between these 2 alterations and their mechanisms remain unclear. The aim of this study was to evaluate the hypothesis of a chronic elevation of circulating NE levels as a mechanism of decreased uptake of radiolabeled NE analogs and reduced beta-adrenergic receptor sites in the heart. METHODS: Osmotic minipumps containing either NE or NaCl were implanted intravenously in rats for 5 d. The uptake-1 function was assessed in vitro by measuring in excised hearts (3)H-NE and (123)I-metaiodobenzylguanidine ((123)I-MIBG) uptakes and uptake-1 carrier density using (3)H-mazindol binding assay. The myocardial beta-adrenergic receptor pathway was assessed in vitro by (3)H-CGP 12177 binding and measurement of adenylyl cyclase activity at baseline and under stimulation. RESULTS: A 34% decrease in (3)H-NE uptake and a 35% decrease in (123)I-MIBG uptake were found in the hearts of rats infused with the NE pump compared with that of rats infused with saline solution (P < 0.05 for both). Moreover, the uptake-1 carrier protein density was decreased by 29% (P < 0.05) and 33% (P < 0.05) in right and left ventricles, respectively, of rats infused with NE compared with those infused with saline solution. Myocardial beta-adrenergic receptor desensitization was associated with a 36% reduction in receptor density in the right ventricle (P < 0.05) and a 31% reduction in the left ventricle (P < 0.05) of rats infused with NE compared with those infused with saline solution. CONCLUSION: The decrease in myocardial beta-adrenergic receptors and radiolabeled NE analog uptake found in different cardiomyopathies using neuroimaging techniques may be related to a functional mechanism of NE-induced downregulation of both beta-adrenergic receptor and uptake-1 carrier sites.


Subject(s)
Heart Ventricles/drug effects , Heart Ventricles/metabolism , Norepinephrine/administration & dosage , Receptors, Adrenergic, beta/metabolism , 3-Iodobenzylguanidine/pharmacokinetics , Adrenergic Uptake Inhibitors/administration & dosage , Animals , Cardiomyopathies/diagnostic imaging , Cardiomyopathies/metabolism , Heart Ventricles/diagnostic imaging , Humans , Infusions, Intravenous , Male , Radionuclide Imaging , Radiopharmaceuticals/pharmacokinetics , Rats , Rats, Wistar , Reference Values , Statistics as Topic
SELECTION OF CITATIONS
SEARCH DETAIL
...